title: Neurobiological effects of Hyperforin and its potential in Alzheimer's disease therapy.
abstract: St. John's Wort (SJW) has been used medicinally for over 5,000 years. Relatively recently, one of its phloroglucinol derivatives, hyperforin, has emerged as a compound of interest. Hyperforin first gained attention as the constituent of SJW responsible for its antidepressant effects. Since then, several of its neurobiological effects have been described, including neurotransmitter re-uptake inhibition, the ability to increase intracellular sodium and calcium levels, canonical transient receptor potential 6 (TRPC6) activation, N-methyl-D-aspartic acid (NMDA) receptor antagonism as well as antioxidant and anti-inflammatory properties. Until recently, its pharmacological actions outside of depression had not been investigated. However, hyperforin has been shown to have cognitive enhancing and memory facilitating properties. Importantly, it has been shown to have neuroprotective effects against Alzheimer's disease (AD) neuropathology, including the ability to disassemble amyloid-beta (Abeta) aggregates in vitro, decrease astrogliosis and microglia activation, as well as improve spatial memory in vivo. This review will examine some of the early studies involving hyperforin and its effects in the central nervous system (CNS), with an emphasis on its potential use in AD therapy. With further investigation, hyperforin could emerge to be a likely therapeutical candidate in the treatment of this disease.
authors.affiliation: CARE & CRCP, Biomedical, Center, P. Universidad Católica de Chile, P.O. Box 114-D, Santiago, Chile.
authors.forename: T N
authors.initials: TN
authors.lastname: Griffith
authors.forename: L
authors.initials: L
authors.lastname: Varela-Nallar
authors.forename: M C
authors.initials: MC
authors.lastname: Dinamarca
authors.forename: N C
authors.initials: NC
authors.lastname: Inestrosa
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001643:Bridged Bicyclo Compounds / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy; D020902:Hypericum / Q000737:chemistry; D051379:Mice; D008822:Mice, Transgenic; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010696:Phloroglucinol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D050052:TRPC Cation Channels / Q000378:metabolism; D000074287:TRPC6 Cation Channel; D013729:Terpenes / Q000627:therapeutic use*
chemical_list: D016229:Amyloid beta-Peptides; D000928:Antidepressive Agents; D001643:Bridged Bicyclo Compounds; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; D050052:TRPC Cation Channels; D000074287:TRPC6 Cation Channel; D013729:Terpenes; C492146:Trpc6 protein, mouse; D010696:Phloroglucinol; C001654:hyperforin